US2006135464A1PendingUtilityA1

Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues

63
Individually held — no corporate assignee on recordPriority: Sep 22, 1999Filed: Feb 6, 2006Published: Jun 22, 2006
Est. expirySep 22, 2019(expired)· nominal 20-yr term from priority
Inventors:B. Ron Johnson
A61K 31/522A61K 31/205A61K 31/53A61K 45/06A61K 9/0014A61K 31/4425A61K 31/675A61K 31/7076A61K 31/055A61M 35/003A61K 47/10A61K 47/08A61K 31/155A61K 31/7072
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions, methods and systems for treating disordered epithelial tissues, such as is caused by pathogens and/or by toxins produced thereby. The invention relates to the use of an anti-infective and/or antimicrobial active agent in a carrier, with vigorous agitation of the disordered epithelial tissue for topical treatment thereof under such conditions sufficient to achieve clinically discernable improvement of the disordered epithelial tissue. The preferred anti-infective and/or antimicrobial active agent comprises a nucleoside, such as acyclovir, valcyclovir, penciclovir, famciclovir, ganciclovir, cidofovir, adefovir, and tenofovir, and derivatives, analogs, or metabolites thereof, or a mixture thereof, or 1-docosanol, optionally in combination with an organohalide. The inventive compositions and methods may employ the use of an applicator adapted for use in promoting the penetration of the treatment composition and/or the vigorous agitation of the disordered tissue.

Claims

exact text as granted — not AI-modified
1 . An anti-viral composition for treating disordered tissue caused by a virus, comprising: 
 a nucleoside; and    a liquid carrier comprising a tissue penetrating component for penetrating skin in a rapid manner without rapidly diffusing beyond the skin.    
   
   
       2 . An anti-viral composition as recited in  claim 1 , wherein the nucleoside is in the form of a salt, phosphate ester, acyl derivative, or other derivative.  
   
   
       3 . An anti-viral composition as recited in  claim 1 , wherein the nucleoside comprises an acyclic nucleoside.  
   
   
       4 . An anti-viral composition as recited in  claim 3 , wherein the acyclic nucleoside is selected from the group comprising acyclovir, penciclovir, and famciclovir.  
   
   
       5 . An anti-viral composition as recited in  claim 3 , wherein the acyclic nucleoside is selected from the group comprising analogs of acyclovir, analogs of penciclovir, and analogs of famciclovir.  
   
   
       6 . An anti-viral composition as recited in  claim 5 , wherein the analogs of acyclovir, penciclovir, and famciclovir comprise at least one of salts, phosphate esters, acyl derivatives, or metabolites thereof.  
   
   
       7 . An anti-viral composition as recited in  claim 1 , wherein the nucleoside is selected from the group comprising valcyclovir, ganciclovir, cidofovir, adefovir, tenofovir, and analogs of the foregoing.  
   
   
       8 . An anti-viral composition as recited in  claim 7 , wherein the analogs of valcyclovir, ganciclovir, cidofovir, adefovir, and tenofovir comprise at least one of salts, phosphate esters, acyl derivatives, or metabolites thereof.  
   
   
       9 . An anti-viral composition as recited in  claim 1 , further comprising an organohalide.  
   
   
       10 . An anti-viral composition as recited in  claim 1 , further comprising 1-docosonal.  
   
   
       11 . An anti-viral composition as recited in  claim 10 , wherein said at least one benzalkonium chloride compound comprises benzalkonium chloride having an n-alkyl chain length that is at least one of C 12 , C 14 , C 16 , or C 18 .  
   
   
       12 . An anti-viral composition as recited in  claim 1 , wherein the liquid carrier comprises isopropyl alcohol.  
   
   
       13 . An anti-viral composition as recited in  claim 1 , wherein the liquid carrier comprises isopropyl alcohol and water.  
   
   
       14 . An anti-viral composition as recited in  claim 1 , wherein the liquid carrier comprises isopropyl alcohol and water, the water being in an amount ranging form about 20% to about 40% by volume of the carrier.  
   
   
       15 . An anti-viral composition as recited in  claim 1 , wherein the liquid carrier comprises an aqueous solution of isopropyl alcohol at a concentration in a range of about 20% to about 90% of isopropyl alcohol by volume of the carrier.  
   
   
       16 . An anti-viral composition as recited in  claim 1 , wherein the liquid carrier comprises an aqueous solution of isopropyl alcohol at a concentration in a range of about 30% to about 85% of isopropyl alcohol by volume of the carrier.  
   
   
       17 . An anti-viral composition as recited in  claim 1 , wherein the liquid carrier comprises an aqueous solution of isopropyl alcohol at a concentration in a range of about 40% to about 80% of isopropyl alcohol by volume of the carrier.  
   
   
       18 . An anti-viral composition as recited in  claim 1 , wherein the carrier comprises at least one of acetone, acetic acid, or acetic anhydride, ethanol, methanol, cetyl alcohol, or benzyl alcohol.  
   
   
       19 . An anti-viral composition as recited in  claim 1 , wherein the treatment composition is substantially free of tissue penetration inhibiting components.  
   
   
       20 . An anti-viral composition as recited in  claim 1 , wherein the treatment composition penetrates into disordered tissue such that the treatment composition is no longer visibly detectable on the disordered tissue within about two minutes after application of the treatment composition onto the disordered tissue.  
   
   
       21 . An anti-viral composition as recited in  claim 1 , wherein the nucleoside has a concentration in a range from about 0.01% to about 50% by weight of the treatment composition.  
   
   
       22 . An anti-viral composition as recited in  claim 1 , wherein the nucleoside has a concentration in a range from about 0.075% to about 20% by weight of the treatment composition.  
   
   
       23 . An anti-viral composition as recited in  claim 1 , wherein the nucleoside has a concentration in a range from about 0.2% to about 15% by weight of the treatment composition.  
   
   
       24 . An anti-viral composition as recited in  claim 1 , wherein the nucleoside has a concentration in a range from about 0.5% to about 10% by weight of the treatment composition.  
   
   
       25 . An anti-viral composition for treating disordered tissue caused by a virus, comprising: 
 at least one of a nucleoside or 1-docosonal; and    a liquid carrier comprising a tissue penetrating component for penetrating skin in a rapid manner without rapidly diffusing beyond the skin.    
   
   
       26 . A method for treating viral-induced disordered tissue, comprising: 
 identifying disordered tissue that comprises one or more lesions caused by a virus; and    applying an effective amount of the treatment composition of  claim 25  to a surface of the disordered tissue and causing and/or allowing the treatment composition to penetrate into the disordered tissue.    
   
   
       27 . A method for treating viral-induced disordered tissue, comprising: 
 identifying disordered tissue that comprises one or more lesions caused by a virus; and    applying an effective amount of a treatment composition to a surface of the disordered tissue and causing and/or allowing the treatment composition to penetrate into the disordered tissue, the treatment composition comprising a nucleoside in a liquid carrier comprising a tissue penetrating agent for penetrating skin in a rapid manner.    
   
   
       28 . The method as recited in  claim 27 , further comprising delivering the treatment composition to the disordered tissue using an applicator and by vigorously agitating the disordered tissue with the applicator.  
   
   
       29 . The method as recited in  claim 28 , wherein said applicator is frictionally rubbed across the skin surface.  
   
   
       30 . The method as recited in  claim 28 , wherein said applicator is non-frictional moved so that the skin surface moves substantially in concert with the applicator.  
   
   
       31 . The method as recited in  claim 28 , wherein said applicator is pressed against the disordered tissue with sufficient pressure in order to firmly compress the disordered tissue against underlying tissue.  
   
   
       32 . A method for treating viral-induced disordered tissue, comprising: 
 identifying disordered tissue that comprises one or more lesions caused by a virus; and    applying an effective amount of a treatment composition to a surface of the disordered tissue, the treatment composition comprising at least one of a nucleoside or 1-decosanol in a liquid carrier, the treatment composition being applied while applying sufficient pressure to the disordered tissue so as to firmly compress the disordered tissue against bone, tooth, gum, or other tissue underlying the disordered tissue in order to assist penetration of the treatment composition into the disordered tissue.    
   
   
       33 . A method as recited in  claim 32 , wherein the carrier comprises an aqueous solution of water and at least one organic solvent.  
   
   
       34 . A method as recited in  claim 32 , wherein the carrier comprises water and isopropyl alcohol.  
   
   
       35 . A method as recited in  claim 32 , wherein the treatment composition is applied to the disordered tissue using an applicator.  
   
   
       36 . A method as recited in  claim 32 , wherein the treatment composition is applied to the disordered tissue using a finger.

Join the waitlist — get patent alerts

Track US2006135464A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.